TY - JOUR
T1 - Antinociceptive, hypoglycemic and spasmolytic effects of Brickellia veronicifolia
AU - Palacios-Espinosa, Francisco
AU - Déciga-Campos, Myrna
AU - Mata, Rachel
N1 - Funding Information:
This work was supported by grants of Consejo Nacional de Ciencia y Tecnología (CONACyT, Proyecto C01-018) and DGAPA-UNAM IN212005. The technical assistance of Isabel Rivero-Cruz, Laura Acevedo, Rosa del Villar, Marisela Gutiérrez and Georgina Duarte-Lisci is also recognized. Francisco Palacios-Espinosa acknowledges fellowships from CONACyT, to carry out graduate studies.
PY - 2008/8/13
Y1 - 2008/8/13
N2 - Introduction: Brickellia veronicifolia (Kunth) Gray (Asteraceae) (BV) is broadly commercialized for treating gastrointestinal diseases (stomach aches, biliary colics and dyspepsia), arthritis, diabetes and painful inflammatory complaints. Aims of the study: In order to complete the preclinical pharmacological profile of BV, first the antinociceptive effect of an organic extract (BVE) and isolated metabolites on the hot plate and writhing tests was assessed. Experimental: Then, their potential hypoglycemic effects were analyzed in normoglycemic and diabetic rats; in addition, an oral glucose tolerance test (OGTT) was performed. Finally, the spasmolytic activity of BVE was assessed in vivo using the gastrointestinal motility test (GMT) in mice. Results: The results revealed that BVE (100-600 mg/kg), 6-methoxysalicylic acid (1), 2-methoxybenzoic acid (2), benzyl-2,6-dimethoxybenzoate (3), and taraxasteryl acetate (4) showed significant analgesic effects. Compounds 2 and 3 were the most active (1-100 mg/kg) in the hot plate and writhing tests, respectively. In the antidiabetic assays, BVE (100 mg/kg) showed an important hypoglycemic action. Furthermore, at the same dose, it provoked a significant postprandial decrease of blood glucose level after 30 min of a glucose challenge. Finally, the GMT in mice revealed the spasmolytic activity in vivo of BVE (31.6 mg/kg). Conclusion: The overall information tends to support the vernacular uses of the plant.
AB - Introduction: Brickellia veronicifolia (Kunth) Gray (Asteraceae) (BV) is broadly commercialized for treating gastrointestinal diseases (stomach aches, biliary colics and dyspepsia), arthritis, diabetes and painful inflammatory complaints. Aims of the study: In order to complete the preclinical pharmacological profile of BV, first the antinociceptive effect of an organic extract (BVE) and isolated metabolites on the hot plate and writhing tests was assessed. Experimental: Then, their potential hypoglycemic effects were analyzed in normoglycemic and diabetic rats; in addition, an oral glucose tolerance test (OGTT) was performed. Finally, the spasmolytic activity of BVE was assessed in vivo using the gastrointestinal motility test (GMT) in mice. Results: The results revealed that BVE (100-600 mg/kg), 6-methoxysalicylic acid (1), 2-methoxybenzoic acid (2), benzyl-2,6-dimethoxybenzoate (3), and taraxasteryl acetate (4) showed significant analgesic effects. Compounds 2 and 3 were the most active (1-100 mg/kg) in the hot plate and writhing tests, respectively. In the antidiabetic assays, BVE (100 mg/kg) showed an important hypoglycemic action. Furthermore, at the same dose, it provoked a significant postprandial decrease of blood glucose level after 30 min of a glucose challenge. Finally, the GMT in mice revealed the spasmolytic activity in vivo of BVE (31.6 mg/kg). Conclusion: The overall information tends to support the vernacular uses of the plant.
KW - 2-Methoxybenzoic acid
KW - 6-Methoxysalicylic acid
KW - Antinociceptive
KW - Asteraceae
KW - Benzyl-2,6-dimethoxybenzoate
KW - Brickellia veronicifolia
KW - Hypoglycemic
UR - http://www.scopus.com/inward/record.url?scp=47749118710&partnerID=8YFLogxK
U2 - 10.1016/j.jep.2008.05.012
DO - 10.1016/j.jep.2008.05.012
M3 - Artículo
C2 - 18583074
SN - 0378-8741
VL - 118
SP - 448
EP - 454
JO - Journal of Ethnopharmacology
JF - Journal of Ethnopharmacology
IS - 3
ER -